- Home
- TXN vs ABBV Comparison
TXN vs ABBV Comparison
Compare TXN & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXN | ABBV |
|---|---|---|
| Founded | 1930 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.7B | 358.5B |
| IPO Year | 2002 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TXN | ABBV |
|---|---|---|
| Price | $296.36 | $247.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 18 |
| Target Price | ★ $265.46 | $253.71 |
| AVG Volume (30 Days) | ★ 8.1M | 4.1M |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | 2.11% | ★ 3.39% |
| EPS Growth | ★ 4.81 | N/A |
| EPS | ★ 1.68 | 0.39 |
| Revenue | $17,682,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $11.74 | $11.87 |
| Revenue Next Year | $10.43 | $8.12 |
| P/E Ratio | ★ $185.43 | $625.28 |
| Revenue Growth | ★ 13.05 | 8.57 |
| 52 Week Low | $152.73 | $181.75 |
| 52 Week High | $334.03 | $244.81 |
Technical Indicators
Market Signals| Indicator | TXN | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 75.20 |
| Support Level | $273.88 | $213.65 |
| Resistance Level | $310.29 | N/A |
| Average True Range (ATR) | 11.72 | 5.90 |
| MACD | -1.57 | 2.32 |
| Stochastic Oscillator | 36.23 | 99.62 |
Price Performance
Historical ComparisonAbout TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.